can semaglutide cause stroke FDA approves Wegovy to reduce heart attack and risk Wegovy linked to rare “eye

For us to consider medication-driven obesity treatments as equivalent to bariatric surgery, it's essential that they demonstrate mortality benefits across all obesity patients, including those who do not have cardiovascular disease or diabetes

Upon administration, semaglutide exhibits a prolonged half-life of approximately one week, which is significantly longer than many other pharmacological agents

Please see Medication Guide and Prescribing Information, Including Boxed Warning, for Wegovy at About obesity and cardiovascular disease (CVD) Obesity is a serious chronic, progressive, and misunderstood disease that requires long-term management

Although rare, it can become life-threatening if not treated promptly

these medications are FDA-approved for specific indications